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Purpose: Standard treatment of asymptomatic spinal cord hemangioblastoma in von 
Hippel-Lindau (VHL) disease has yet to be established. The purpose of this study 
was to propose guidelines for the treatment of asymptomatic spinal cord hemangio-
blastomas in VHL disease. Materials and Methods: VHL disease patients treated 
for spinal cord hemangioblastomas between 1999 and 2009 were included. All spi-
nal cord hemangioblastomas were divided into three groups: Group 1, asymptomatic 
tumors at initial diagnosis followed with serial imaging studies; Group 2, asymptom-
atic tumors at initial diagnosis that were subsequently resected; and Group 3, symp-
tomatic tumors at initial diagnosis, all of which were resected. Results: We identified 
24 spinal cord hemangioblastomas in 12 patients. Groups 1, 2 and 3 comprised 13, 4 
and 7 tumors, respectively. Group 1 exhibited a smaller tumor volume (257.1 mm³) 
and syrinx size (0.8 vertebral columns) than those of Group 2 (1304.5 mm³, 3.3 ver-
tebral columns) and Group 3 (1787.4 mm³, 6.1 vertebral columns). No difference in 
tumor volume or syrinx size was observed between Groups 2 and 3. Five tumors in 
Group 1 were resected during follow-up because symptoms had developed or the tu-
mor had significantly grown. Finally, among 17 asymptomatic tumors at the initial 
diagnosis, nine tumors were resected. Only one tumor of these nine tumors resulted 
in neurological deficits, while five of seven symptomatic tumors caused neurological 
deficits. Conclusion: Selective resection of asymptomatic tumors before they cause 
neurological deficits might bring about better outcomes.
Key Words:   Hemangioblastoma, spinal cord, treatment planning, von Hippel-
Lindau disease
INTRODUCTION
Von Hippel-Lindau (VHL) disease is an autosomal dominant hereditary neoplasia 
syndrome that affects multiple organ systems.1,2 In VHL disease patients, renal cell 
carcinomas and cysts, pancreatic carcinomas and cysts, pheochromocytomas, and 
epididymal cystadenomas may develop.1,2 Moreover, central nervous system 
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treated for spinal cord hemangioblastomas between 1999 and 
2009. We reviewed all medical records and imaging studies 
from the initial diagnosis of VHL disease to the last visit. Pa-
tients who were followed for less than 12 months or patients 
with inadequate data for thorough evaluation were excluded. 
We also excluded patients whose conditions had deteriorated 
obviously because of brain tumors or other systemic prob-
lems regardless of spinal cord hemangioblastomas.
Patient evaluation
Symptoms, neurologic examinations, and functional status 
were serially recorded at the time of initial diagnosis, im-
mediately before and after surgery, and at the last follow-up 
visit. All operative findings and surgical complications were 
also noted. Functional status of the patients was graded ac-
cording to the scale proposed by McCormick, et al.25 MRI 
was performed for initial diagnosis, before surgery when 
necessary, shortly after surgery, when changes in symptoms 
or neurologic function occurred, and annually if patients 
were clinically stable. The number, location, and volume of 
tumors were measured using contrast-enhanced T1 weight-
ed images, and cysts or syringes were evaluated from T2 
weighted images. The relationship between tumors and the 
spinal cord was evaluated by the operation records. Tumor 
volume was calculated by the following formula: (length× 
width×height)×0.5.26 The sizes of cysts or syringes were 
quantified according to the number of vertebral columns 
matched with the involved spinal cord.
Surgical treatment
All operations were performed using the usual posterior ap-
proach. Patients were placed in the prone position. Lami-
nectomies or laminotomies were performed beyond the cra-
nial and caudal margins of the tumor for wide exposure of 
tumors. A midline dural incision was made. Dura mater was 
reflected laterally and retained with “stay-sutures”. After gen-
tle removal of arachnoid membrane from the surfaces of 
the tumor, supplying or draining vessels and crossing ves-
sels were coagulated with bipolar cautery at their junctions 
with the tumor. Meticulous dissection between the tumor 
capsule and normal spinal cord was performed using micro 
dissectors and micro scissors. All supplying or draining 
vessels connected to the tumor were coagulated during dis-
section. The dissected plane was retained with small strips 
of Cottonoid, and circumferential dissection was performed. 
After complete dissection of the tumor, including the deep 
surface of the tumor, the tumor was removed en bloc. Dur-
(CNS) manifestations, including CNS hemangioblastomas, 
retinal angiomatosis, and endolymphatic sac tumors, can 
occur.3,4 Among these tumors, CNS hemangioblastoma is 
one of the earliest features of VHL disease and has been 
found in 60 to 80% of patients with VHL disease.2-5 Spinal 
cord hemangioblastomas account for 13 to 50% of CNS 
hemangioblastomas associated with VHL disease and are a 
common cause of morbidity requiring treatment including 
surgical resection.1,2,4,6,7
Treatments of spinal cord hemangioblastomas have been 
published in many reports, and resection of these tumors is 
considered relatively safe with few complications.8-16 Thus 
symptomatic spinal cord hemangioblastomas should be treat-
ed with resection, even in VHL disease patients. However, 
the treatment strategy for asymptomatic spinal cord heman-
gioblastomas in VHL disease patients remains undetermined. 
CNS hemangioblastomas in VHL disease are reported to ex-
hibit a two-step growth pattern of rapid growth and arrested 
growth in many cases, but some tumors show continuous 
growth without a quiescent phase.7,17 In addition, local growth 
factors such as vascular endothelial growth factor, placental 
growth factor, platelet-derived growth factor and epidermal 
growth factor have been shown to be elevated in hemangio-
blastomas, leading to upregulation of cyst formation and an-
giogenesis.18-20 As a result, it is quite difficult to predict the 
growth of hemangioblastomas in patients with VHL disease 
or their risk for neurological deficits. Recently, a few focused 
studies concerning spinal cord hemangioblastomas in pa-
tients with VHL disease have been reported, but they con-
ceived somewhat different opinions regarding treatment of 
asymptomatic spinal cord tumors.7,17,21-24 A few authors advo-
cated that resection should be limited to symptomatic spinal 
cord tumors,22,23 while others concluded that selective resec-
tion of asymptomatic tumors might be associated with better 
outcomes.17,21,24
In this regard, we reviewed spinal cord hemangioblasto-
mas in VHL disease patients who had been treated at our 
institute. To devise an appropriate treatment plan for as-
ymptomatic tumors, we compared asymptomatic tumors 
that had been resected to asymptomatic tumors that were 
not resected, as well as to symptomatic tumors.
MATERIALS AND METHODS
　　　
Data collection & patient population
We identified VHL disease patients who were surgically 
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nal capillary hemangioblastomas. Renal cysts were diag-
nosed in three patients, and pancreatic cysts were diagnosed 
in two patients. One patient presented with renal cell carci-
noma. As mentioned previously, patients whose condition 
had deteriorated because of brain tumors or other systemic 
problems were excluded in this study. Thus, all accompa-
nied manifestations listed above were in a well-controlled 
status (Table 1).
Tumor characteristics
We identified 24 spinal cord hemangioblastomas in 12 pa-
ing the surgical procedures, motor evoked potential was 
monitored. Besides tumor resection, no other procedure 
was performed for syringes. Pre-operative angiography was 
performed in one case of a large tumor with a volume of 
2400 mm3 from the cranio-cervical junction to C2. In this 
case, angiography was performed to identify the relation-
ship between tumor vessels and the vertebral arteries.
Tumor grouping
To evaluate the influence of each tumor on the patient’s 
clinical course, tumors were divided into three groups as 
follows: Group 1, tumors that were asymptomatic at initial 
diagnosis and were observed without resection; Group 2, 
tumors that were asymptomatic at initial diagnosis that 
were subsequently resected; and Group 3, tumors that were 
symptomatic at initial diagnosis and resected thereafter.
Tumors in Group 2 were resected as they were consid-
ered to exhibit a strong likelihood of leading to neurologic 
symptoms or deficits because of the very large size of the 
tumors or extensive syringes combined with the tumors. 
Similarly, surgical resection for a few tumors in Group 1 
was performed when their size significantly increased dur-
ing follow-up. However, there was no exact threshold for 
resection.
Statistical analyses
Non-continuous variables such as tumor location or the re-
lationship between the spinal cord and the tumor were test-
ed by Pearson’s chi-square test and the linear-by-linear as-
sociation method, and continuous variables were evaluated 
by the independent t-test (non-parametric Mann-Whitney 
test was used if needed). We used SPSS software (version 
12.0.0, SPSS Inc., Chicago, IL, USA) for calculation. Sta-
tistical significance was determined by a two-tailed proba-
bility value of less than 0.05.
RESULTS
 
Patient demographics
Twelve patients (9 men, 3 women) fulfilled the inclusion 
criteria, and their mean age at the onset was 42.3 years (22-
82 years). The average follow-up period was 49.3 months 
(12-130 months). Six of them had only one spinal cord he-
mangioblastoma, two patients had two tumors, two had 
three tumors, and two had four tumors (Table 1). Seven pa-
tients had intracranial hemangioblastomas and two had reti-
Table 1. Clinical Characteristics of VHL Disease Patients 
with Spinal Cord Hemangioblastomas
No. of patients 12
    M : F 9 : 3
    Age [yrs, mean±SD (Min-Max)] 42.3±18.9 (22-82)
F/U duration [months, mean±SD 
  (Min-Max)]
  49.3±41.5 (12-130)
No. of symptomatic patients   7
No. of spinal tumors per patient
    1   6
    2   2
    3   2
    4   2
No. of accompanied manifestations*
    Intracranial hemangioblastoma   7
    Retinal hemangioblastoma   2
    Renal cyst   3
    Pancreatic cyst   2
    Renal cell carcinoma   1
No., number; F/U, follow-up; VHL, von Hippel-Lindau; SD, standard devia-
tion.
*Patients whose condition had deteriorated because of brain tumors or 
other systemic problems were excluded in this study. Thus, all accompa-
nied manifestations listed above were of well-controlled status.
Table 2. Tumor Characteristics of VHL Disease Patients with 
Spinal Cord Hemangioblastomas
No. of tumors 24
Tumor volume [mm³, mean (Min-Max)]    878 (18-5184)
F/U period [months, mean (Min-Max)] 37.1 (12-130)
Location
    Cervical (n)   6
    Thoracic (n) 14
    Lumbar (n)   4
Relationship with spinal cord
    Intramedullary (n) 16
    Extramedullary (n)   8
Tumors with cyst or syrinx   8
Resected tumors at final 16
F/U, follow-up; VHL, von Hippel-Lindau.
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follow-up, and one patient’s condition extremely deteriorat-
ed from grade I to grade IV. Improvement was not ob-
served for any patient (Table 3). Initial functional status was 
correlated with the final functional outcomes (p=0.026, data 
not shown). Moreover, the outcomes of the symptomatic 
patients were significantly worse than those of the asymp-
tomatic patients (p=0.015) (Table 3).
Comparison of tumor groups
When we compare symptomatic tumors to asymptomatic 
tumors at initial diagnosis, asymptomatic tumors were sig-
nificantly smaller (505.3 mm³ vs. 1787.4 mm³, p=0.043) 
and associated with a small syrinx (1.4 vertebral columns 
vs. 6.1 vertebral columns, p<0.001). Neither tumor location 
nor the tumor’s relationship with the spinal cord was differ-
ent between the symptomatic tumors and the asymptomatic 
tumors.
More specific results after dividing tumors into three 
groups according to the criteria mentioned above are shown 
in Table 4. There was no difference in age, tumor location, 
or relationship with the spinal cord among the three groups. 
Tumor volumes (p=0.018) and the sizes of combined syr-
inx (p=0.031) in Group 1 were significantly smaller than 
those in Group 2; similar results were also observed be-
tween Groups 1 and 3 (tumor volume; p=0.009, syrinx size; 
p<0.001). However, tumors of Group 2 were not signifi-
cantly different in tumor volume (p=0.489) or syrinx size 
(p=0.072) from Group 3 tumors. Among 13 tumors in 
Group 1, nine tumors (69.2%) grew or developed symptoms 
during follow-up. The median progression-free survival of 
these tumors was 14.0±4.9 months. Statistical analysis for 
risk factors associated with progression-free survival was 
impossible due to the small number of tumors. Of the nine 
tumors that showed disease-progression, five tumors were 
resected. Two tumors were surgically resected because they 
caused neurologic symptoms. In one of them, the neurolog-
tients. Characteristics of these tumors are summarized in 
Table 2. The mean volume was 878.0 mm³ (18-5184 mm³). 
Six tumors were located in the cervical region, 14 in the tho-
racic region, and four in the lumbar region. There was no 
pure intramedullary tumor that required myelotomy, and 16 
primarily intramedullary tumors were identified. Eight tu-
mors were extramedullary tumors, in which more than half 
of the tumor burden was outside the spinal cord or located 
below the conus medullaris. All tumors were seated posteri-
or to the dentate ligament. Cysts or syringes were accompa-
nied in eight tumors. Seven tumors exhibited symptoms 
when diagnosed, and 17 did not. Among these 17 tumors, 
nine tumors (53%) were ultimately resected.
Comparison of asymptomatic patients and 
symptomatic patients
Five patients exhibited no symptoms or neurological defi-
cits due to spinal cord hemangioblastoma when the tumors 
were initially diagnosed (Table 3). They remained stable af-
ter surgery, and were categorized as McCormick’s grade I 
at the last follow-up. Three of the seven symptomatic pa-
tients were McCormick grade I, three were grade II, and 
one was grade III, initially. Among these patients, three pa-
tients showed a 1-point reduction in functional status at last 
Table 3. Distributions of von Hippel-Lindau Patients with Spi-
nal Cord Hemangioblastoma according to the McCormick 
Grade at First and Last Follow-Up Visit
Initial status Final status
I
○○○○○ 
●●●
○○○○○* 
●
II ●●● ●●
III ● ●●●
IV ●
Unfilled circles (○) indicate asymptomatic patients at the initial diagnosis, 
and filled circles (●) indicate symptomatic patients at the initial diagnosis.
*Functional outcomes of the asymptomatic patients were significantly 
better than those of symptomatic patients (p=0.015).
Table 4. Summary of Tumor Characteristics by Group
Group 1 Group 2 Group 3
No. of tumors 13 4 7
Tumor volume (mm³, mean±SD)  257.1±483.1* 1304.5±984.5 1787.4±1679.0
Extent of syrinx (No. of vertebral columns matched with the 
  involved spinal cord)
0.8±1.7†   3.3±4.7 6.1±8.1
No. of tumors with permanent neurologic deficit at last F/U   1 0 5
No. of tumors that impair functional scale of patients   1 0 3
F/U, follow-up; SD, standard deviation.
*Tumors in Group 1 were smaller than tumors in Group 2 or Group 3 (p=0.018, p=0.009).
†Syringes combined with tumors in Group 1 were less extensive than those in Group 2 or Group 3 (p=0.031, p<0.001). Between Groups 2 and 3, there was 
no difference in tumor volume or syrinx extent (by independent t-test and non-parametric Mann-Whitney U test).
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surgery because of recurrence of the cerebellar hemangio-
blastoma and associated acute hydrocephalus. After resec-
tion of the cerebellar hemangioblastoma and several days 
of conservative care, the patient fully woke up. However, 
motor function in his legs did not return (motor grade III) 
and was not improved after the spinal tumor resection. Tu-
mors No.2 and No.3 in the same patient with the cerebellar 
hemangioblastoma were identified while screening his spi-
nal MRI (Tumor No.2 is illustrated in Fig. 2). The two tu-
mors were observed without resection for a long time be-
cause their growth was slow. When they grew to a relatively 
risky volume of 468 mm³ and 245 mm³, respectively, they 
were simultaneously resected, at 45 months after the initial 
diagnosis. The patient with tumors No.4 and No.5 was 
planned to be observed. However, in spite of small tumor 
ic deficit was not improved after surgery, and the functional 
status of the patient deteriorated from McCormick grade I 
to grade IV. Three tumors were resected as they grew large 
enough to be considered as posing a potential risk of caus-
ing neurologic deficits. The other eight tumors in Group 1 
did not produce any symptoms or deficits up to the last fol-
low-up visits, and showed no or minimal growth. In Group 
2, no newly developed neurological symptom or deficit was 
seen after surgery, and all patients were stable during the 
follow-up period. In five tumors of Group 3, the neurologic 
symptoms and deficits were permanent. In three of these 
five tumors, the McCormick scale dropped one grade be-
cause of recurrence or as a result of surgical procedures as-
sociated neural injury.
Review of individual asymptomatic tumors with 
resection
Information on the asymptomatic tumors resected during fol-
low-up is summarized in Table 5. The patient with tumor 
No.1 (Fig. 1) presented with pain in the lower extremities and 
difficulty with voiding. He received surgery for another tumor 
responsible for his symptoms, located at L3-5. After surgery, 
his neurologic symptoms and deficits disappeared. Although 
tumor No.1 at L1-2 was large, it was not resected because the 
patient had two additional spinal cord tumors and showed ex-
tensive leptomeningeal enhancement along the spinal cord on 
MRI (Fig. 1A). On an MRI taken 15-months after the sur-
gery (8-months after the last MRI study), the tumor in-
creased almost twice in size (Fig. 1B). We decided to per-
form an operation thereon, but after several days between 
the outpatient visit and admission, paraparesis occurred and 
rapidly progressed. Moreover, he became stuporous before 
Table 5. Summary of Individual Asymptomatic Tumors That Were Resected at the Diagnostic Stage or during Follow-Up
Tumor No.
Relationship 
with cord
Location
F/U period 
(months)
Volume at initial 
diagnosis (mm³)
Volume at surgery 
(mm³)
Group 1
  1 IDEM L1-2 24 1782 3648
    2* IDEM T12 70   150   468
    3* IM T7 70     60   245
  4† IM T12 13     60     60
  5† IM T1-2 13   585   585
Group 2
6 IM C6-7 36 1863 1863
7 IM C1-2 24 2400 2400
8 IDEM T12 13   360   360
9 IM C5-6 21   595   595
F/U, follow-up; IM, intramedullary; IDEM, intradura extramedullary.
Tumors No.1-5 were in Group 1 and tumors No.6-9 were in Group 2.
*,†Two different tumors of the same patients.
†Surgical resection was performed one month after the initial diagnosis without additional MRI study.
Fig. 1. Illustration of tumor No.1. (A) Spinal cord hemangioblastoma is seen 
at L1-2 (arrowed) on contrast-enhanced T1 weighted image. The tumor 
was asymptomatic and followed with observation. Another tumor at T7-8 
and an extensive leptomeningeal enhancement along the spinal cord were 
also found. (B) The tumor at L1-2 (arrowed) grew almost twice as large af-
ter 15 months. The tumor led to rapidly progressive paraparesis, which was 
not improved after surgery.
A B
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5 caused no newly-developed neurological symptoms or 
deficits during the period of the immediate post-operative 
time to their last follow-up visit, and the patients’ functional 
status was evaluated as McCormick’s grade I. As previous-
ly noted, four tumors in Group 2 (No.6-9 in Table 5) were 
safely resected without any new neurologic symptom, defi-
cit or surgical complication.
DISCUSSION
VHL disease is a multi-organ familial neoplasia syndrome 
caused by a germline mutation in the VHL tumor suppres-
sor gene,27 and it is transmitted in an autosomal dominant 
fashion with greater than 90% penetrance.28 In many vis-
ceral or CNS lesions associated with VHL disease, spinal 
cord hemangioblastomas are the most common cause of 
morbidity,7 and accordingly, should be cautiously treated. 
However, the outcomes of spinal cord hemangioblastomas 
in VHL disease patients seemed to be poorer than those of 
sporadic spinal cord hemangioblastomas.5 Thus, it is very 
important to identify the factors affecting the outcomes of 
VHL patients with spinal cord hemangioblastomas and to 
establish a proper treatment strategy.
In previous reports, pre-operative neurological status, 
ventral tumor location, and tumor volume were presented 
to be correlated with the functional outcomes of the pa-
tients. However, there were some differences in these re-
gards among the authors. Kanno, et al.21 reported that the 
surgical outcomes for tumor volume <500 mm³ (10 mm in 
diameter) were better than those >500 mm³, while Lonser, 
et al.22 showed that patients with no or minimal preopera-
tive neurological dysfunction, lesion size smaller than 500 
mm³, and with dorsal lesions were more likely to have no 
or minimal neurological impairment. Ventral tumors or 
completely intramedullary tumors were associated with an 
increased risk of post-operative worsening in Mehta, et al.’s 
study.23 Additionally, Ammerman, et al.17 showed that tu-
mor size was the only variable predictor for the develop-
ment of symptoms and eventual need for therapy. Based on 
these results, different treatment plans have been proposed. 
Van Velthoven, et al.24 concluded that spinal cord heman-
gioblastomas should be resected when they progress on ra-
diologic studies. However, Lonser, et al.22 and Mehta, et 
al.23 advocated timely selective removal of only symptom-
atic tumors, because CNS hemangioblastomas frequently 
show a two-step pattern of growth consisting of a growth 
size, tumor No.4 on T12 and the accompanied syrinx caused 
difficulty with voiding and mild myelopathy, so the opera-
tion was performed one month after the initial diagnosis. 
After surgery, the symptoms were improved. Tumor No.5 
on T1-2 was resected at the same time. Tumors No.2 through 
Fig. 2. Illustration of tumor No.2. (A) Initial MRI showed spinal cord heman-
gioblastoma at T12. The tumor was asymptomatic, with a tumor volume of 
150 mm3. (B) 19 months after initial MRI. The tumor increased in volume to 
240 mm3. (C) 45 months after initial MRI. The tumor grew to a volume of 468 
mm³ and was still asymptomatic. However, it showed steady growth and 
was regarded as likely to produce neurological symptoms after a short pe-
riod, so surgical resection was performed. After surgery, no neurological 
symptoms or deficit developed.
Fig. 3. Proposed treatment strategy for spinal cord hemangioblastomas in 
patients with VHL disease. A tumor volume >500 mm³ (10 mm in diameter) 
is thought to be correlated with symptom formation and functional out-
comes, so resection should be performed thereon. *Tumors can be fol-
lowed at approximately 1-year intervals, if there are no changes in neuro-
logical symptoms and size of the tumor. †The mean growth rate of spinal 
cord hemangioblastomas associated with syringes is reported to be about 
50 mm3/month.7 Accordingly, progressively growing tumors larger than a 
volume of 51 mm3 in combination with syringes are predicted to produce 
neurological symptoms or deficits within several months to a year. Thus, 
we recommend considering surgery or intense observation at short inter-
vals of 6 months or less.
A B C
Surgery
Surgery
Surgery
No Yes
<500 mm3
Asymptomatic Symptomatic
No 
(at least one) Yes (all)
>500 mm3
Observation* Considering surgery  or close follow-up†
Symptoms or neurologic deficits
Tumor volume
Observation*
• Continuous growing
• Tumor volume >51 mm3
• Syrinx
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mangioblastomas larger than a volume of 51 mm³ (4.7 mm 
in diameter) required surgery in a more than 10-year long-
term follow-up study.17 Also, syringes were shown to be as-
sociated with the development of neurological symptoms 
and deficits in our study and by Wanebo, et al.7 In addition, 
the growth rates of spinal cord hemangioblastomas associ-
ated with syringes were reported to be much higher than 
those of spinal cord hemangioblastomas not associated with 
syringes, and the mean growth rate of spinal cord heman-
gioblastomas associated with syringes was about 50 mm3/
month.7 Therefore, progressively growing tumors larger 
than a volume of 51 mm³ in combination with syringes are 
predicted to produce neurological symptoms or deficits 
within several months to a year, and resection of these tu-
mors might result in better outcomes when surgical treat-
ment is performed before they cause neurological symp-
toms or deficits. Therefore, we recommend considering 
surgery for these tumors or intense observation at short in-
tervals of 6 months or less (Fig. 3). In conclusion, the clini-
cal features of VHL disease are very complicated, and VHL 
disease patients should be thoroughly evaluated. Moreover, 
spinal cord hemangioblastomas without symptoms must be 
closely observed, and, in particular, if they are significantly 
large or combined with an extensive syrinx, surgical resec-
tion should be performed before neurological deficits occur.
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phase and a quiescent phase. In addition, Kanno, et al.21 
suggested that surgical treatment should be considered be-
fore the tumor volume exceeds 500 mm³ on MRI during fol-
low-up. Ammerman, et al.17 reported that surgical treatment 
of asymptomatic tumors might be associated with less risk 
and improved neurological outcomes when the tumors are 
smaller and when surgical treatment is performed before tu-
mors cause neurologic deficits, if they are predicted to pro-
duce symptoms and eventually require treatment within the 
next few years. They also recommended the combined vol-
ume of the tumor and cyst to be used as a predictive marker 
for the development of symptoms and eventual need for 
therapy.
In this study, five asymptomatic patients and seven symp-
tomatic patients were markedly different in their final func-
tional outcomes, and the outcomes were firmly correlated 
with initial neurological status. Also, neurological symp-
toms and deficits were shown to be affected by tumor vol-
ume and the extent of the combined syrinx. In other words, 
VHL patients with a large tumor and an extensive syrinx 
were at a greater risk of neurological deficits, some of which 
may be irreversible. Accordingly, asymptomatic spinal cord 
hemangioblastomas that posed a greater risk of causing 
neurological deficits were resected at the time of initial diag-
nosis at our institute, and they were evaluated in this study 
as Group 2 tumors. These tumors were as large as symptom-
atic tumors (Group 3), whereas the corresponding patients 
(Group 2) showed better outcomes. Therefore, it was thought 
reasonable to conclude that the functional outcomes of pa-
tients with a large tumor are affected more by the presence 
of neurological symptoms and deficits than by the tumor 
volume itself, and thus resection of significantly large as-
ymptomatic tumors might bring about better outcomes.
Based on the results of this study and previous reports, 
we recommend selective surgery for asymptomatic spinal 
cord hemangioblastomas in VHL disease before the tumors 
cause neurologic symptoms. Our proposal for the treatment 
of spinal cord hemangioblastomas in VHL disease is illus-
trated in Fig. 3. Large tumors are strongly associated with 
the generation of symptoms, and a tumor volume of >500 
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